Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2016
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Acronyms MOA
- Sponsors AstraZeneca
- 10 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Jul 2009 Actual initiation date changed from Jan 2009 to Jun 2009 as reported by ClinicalTrials.gov.
- 10 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.